The Zacks Analyst Blog Highlights: Amazon, UnitedHealth, AbbVie, Simon Property and Autodesk

Zacks 分析师博客亮点: Amazon 、 UnitedHealth 、艾伯维(AbbVie)、 Simon Property 和 Autodesk

2019-07-08 22:34:02 Zacks

本文共2196个字,阅读需6分钟

For Immediate Release Chicago, IL –July 8, 2019 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Amazon AMZN, UnitedHealth UNH, AbbVie ABBV, Simon Property Group SPG and Autodesk ADSK. Here are highlights from Friday’s Analyst Blog: Top Stock Reports for Amazon, UnitedHealth and AbbVie The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Amazon, UnitedHealth and AbbVie. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today. You can see all of today’s research reports here >>> Amazon’s shares have outperformed the broader market in the past year (the stock is up +10.8% vs. the +7.4% increase for the S&P 500 as a whole). The Zacks analyst thinks Amazon continues to ride on its aggressive retail strategies, distribution strength and robust Prime program. Moreover, rapid adoption of Prime driven by customer benefits and strengthening grocery services is aiding its top line. Expanding content portfolio of Prime remains a tailwind. Further, strengthening AWS services portfolio, rising number of availability zones and growing adoption are aiding Amazon’s dominance in the cloud space. Improving Alexa skills and growing advertisement business remain major positives. However, intensifying competition in the cloud computing market from the likes of Microsoft Azure and Google cloud is a significant headwind. Heavy investment in fulfillment centers remains a concern. (You can read the full research report on Amazon here >>>). Shares of UnitedHealth have lost -2.8% in the past year, underperforming the Zacks Medical Insurance industry, which has declined -1.4% over the same period. The Zacks analyst likes its strong operating performance, favorable business profile and disciplined enterprise risk management. It stands apart in the industry by virtue of healthcare services, technology and innovations offered by its unit, Optum. Numerous acquisitions made by the company have broadened its business profile and provide benefits of diversification. Its solid balance sheet and consistent cash flow generation has enabled higher investment in business which will drive long term growth. Capital management by dividend payment and share buyback is another positive. However, slowdown of growth in international operations and underperformance in Medicaid business are concerns. An increase in leverage and interest burden raises financial risk. (You can read the full research report on UnitedHealth here >>>). AbbVie’s shares have declined -21.3% year to date, underperforming the Zacks Large-Cap Pharmaceuticals industry's increase of +4.7%. The Zacks analyst thinks AbbVie’s key drug, Humira is performing well based on strong demand trends despite new competition. Imbruvica has multibillion dollar potential. AbbVie has been successful in expanding approvals for its cancer drugs, Imbruvica and Venclexta. Moreover, AbbVie has an impressive late-stage pipeline comprising several products with multibillion-dollar potential expected to be launched in the near term. The acquisition of Allergan, if successful, will add the former’s blockbuster Botox to AbbVie’s portfolio. Sales erosion due to direct biosimilar competition to Humira in international markets will be a major headwind in 2019. Estimates have gone down ahead of Q2 earnings. However, AbbVie has a positive record of earnings surprises in the recent quarters. (You can read the full research report on AbbVie here >>>). Other noteworthy reports we are featuring today include Simon Property Group and Autodesk. Breakout Biotech Stocks with Triple-Digit Profit Potential The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases. Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better. See these 7 breakthrough stocks now>> Media Contact Zacks Investment Research 800-767-3771 ext. 9339 support@zacks.com                                       https://www.zacks.com Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
有关即时发布 芝加哥,伊利诺伊州——2019年7月8日——萨克斯。com 公布分析师博客上的股票名单。Zacks 股票研究分析师每天都会讨论影响股票和金融市场的最新消息和事件。最近在博客中出现的股票包括: Amazon AMZN 、 UnitedHealth UNH 、艾伯维(AbbVie) ABBV 、 Simon Property Group SPG 和 Autodesk ADSK 。 以下是周五分析师博客的亮点: Amazon 、 UnitedHealth 和艾伯维(AbbVie)的顶级股票报告 Zacks 研究日报提供了我们分析团队的最佳研究成果。今天的《研究日报》刊登了关于16种主要股票的新研究报告,包括亚马逊、 UnitedHealth 和艾伯维(AbbVie)。这些研究报告是从我们的分析师团队今天发表的大约70份报告中手工挑选出来的。 你可以在这里看到今天所有的研究报告>> 过去一年,亚马逊的股价表现优于大盘(该股上涨了+10.8%,而标普500指数整体上涨了+7.4%)。Zacks 分析师认为,亚马逊继续利用其激进的零售策略、分销实力和强大的 Prime 计划。此外,在客户利益和强化食品杂货服务的推动下,快速采用 Prime 正帮助其实现盈利。扩展 Prime 的内容组合仍是顺风。 此外,加强 AWS 服务组合、增加可用性区域的数量以及越来越多的采用,正帮助亚马逊在云领域占据主导地位。提高 Alexa 技能和不断增长的广告业务仍然是主要的积极因素。 然而,微软( Microsoft Azure )和谷歌( Google )等公司在云计算市场的竞争日益加剧,是一个重大障碍。对执行中心的大量投资仍然是一个问题。 (您可以在此阅读关于 Amazon 的完整研究报告>>)。 联合健康的股价在过去一年中下跌了-2.8%,表现逊于 Zacks 医疗保险行业,后者同期下跌了-1.4%。Zacks 分析师喜欢其强劲的经营业绩、良好的业务形象和严格的企业风险管理。凭借旗下的 Optum 提供的医疗服务、技术和创新,该公司在行业中脱颖而出。 该公司进行了大量收购,扩大了业务范围,并提供了多样化的好处。其稳健的资产负债表和持续的现金流创造使更高的投资业务,将推动长期增长。 通过股息支付和股票回购进行资本管理是另一个积极因素。然而,国际业务增长放缓和医疗补助业务表现不佳是令人担忧的问题。杠杆和利息负担的增加会增加财务风险。 (您可以在此阅读关于 UnitedHealth 的完整研究报告>>)。 艾伯维(AbbVie)的股价今年迄今已下跌-21.3%,逊于 Zacks 大型制药公司+4.7%的涨幅。Zacks 分析师认为,艾伯维(AbbVie)的关键药物 Humira 表现良好,是基于强劲的需求趋势,尽管出现了新的竞争。伊布吕维奇有数十亿美元的潜力。 艾伯维(AbbVie)成功地扩大了对其癌症药物 Imbruvica 和 Venclexta 的批准。此外,艾伯维(AbbVie)拥有令人印象深刻的后期管道,包括几个产品,预计将在近期推出数十亿美元的潜力。收购艾尔建(Allergan)如果成功,将把前者的畅销肉毒杆菌毒素( Botox )纳入艾伯维(AbbVie)的投资组合。 在国际市场上,与 Humira 直接竞争造成的销售流失将是2019年的主要逆风。第二季度收益之前的估计已经下降。然而,艾伯维(AbbVie)在最近几个季度的盈利意外中有着积极的记录。 (您可以阅读关于艾伯维(AbbVie)的完整研究报告>>)。 其他值得注意的报告,我们今天的特色包括西蒙物业集团和 Autodesk 。 三位数利润潜力的生物技术股票 到2024年,随着科学家开发出治疗数千种疾病的方法,生物技术产业预计将突破7750亿美元。他们还找到了编辑人类基因组的方法,从字面上消除我们对这些疾病的脆弱性。 Zacks 刚刚发布的世纪生物学:7生物技术股票购买权利现在,以帮助投资者从7个股票盈利准备好跑赢。我们最近的生物技术推荐在短短一个月内就实现了+98%、+119%和+164%的增长。本报告中的股票可能表现更好。 现在看这7只突破性股票> 媒体联系人 Zacks 投资研究 800-767-3771 ext 。9339 support @ zacks.com https://www.zacks.com 过去的表现并不能保证将来的结果.任何投资固有的潜在损失。本材料仅供参考之用,本材料不构成投资、法律、会计或税务建议,也不构成购买、出售或持有证券的建议。对于任何投资是否适合某一特定投资者,没有提出建议或建议。不应假定在确定和描述的证券、公司、部门或市场上的任何投资是或将是盈利的。所有信息截至本协议签订之日均为最新信息,如有变更,恕不另行通知。所表达的任何观点或观点都不能反映公司整体的观点或观点。Zacks 投资研究公司不从事任何证券的投资银行业务、做市或资产管理活动。这些收益来自假设投资组合,包括 Zacks Rank =1的股票,这些股票每月重新平衡,交易成本为零。这些不是股票实际投资组合的回报。标准普尔500指数是一个非管理指数。有关本新闻稿中显示的性能号码的信息,请访问 https://www.zacks.com/performance\160;

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文